Compare iShares MSCI China ETF (MCHI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Sanofi SA — how do they compare? iShares MSCI China ETF trades at $52.55 (market cap $5.94B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 16× iShares MSCI China ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Sanofi SA for 94 Days on average.
| MCHI | SNY | |
|---|---|---|
Market Cap | $5.94B | $95.18B |
Volume | 1,575,471 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $52.34 |
52-Week Low | $50.48 | $39.51 |
Typical Hold Time | 63 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $51.36, down 0.54% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights trade tensions ahead of U.S.-China talks, though corporate profits surged 26% in Q2. Technical indicators show oversold conditions with RSI at 25.44 suggesting potential for near-term bounce.
The outlook remains cautious given China's macroeconomic pressures and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations versus U.S. indices. Key risks include potential export controls, protectionism threats, and China's reliance on infrastructure spending rather than broad stimulus to support growth.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
